Common mutations in DDR-associated genes, such as BRCA2 and ATM, in CDX2-suppressed cancers may offer additional therapeutic opportunities for treatment with PARP inhibitors or inhibitors of ATM that are in development [30,31]. Here, BRCA2 is linked to cancer.